Literature DB >> 23728613

Accelerated immunotherapy schedules.

Christopher W Calabria1.   

Abstract

Rush and cluster immunotherapy schedules are accelerated immunotherapy build-up schedules. A cluster immunotherapy schedule involves the patient receiving several allergen injections (generally 2-4) sequentially in a single day of treatment on nonconsecutive days. The maintenance dose is generally reached in 4-8 weeks. In rush immunotherapy protocols, higher doses are administered at 15- to 60-min intervals over a 1- to 3-day period until the maintenance dose is achieved. This review will serve as an update for accelerated immunotherapy schedules. The review will include recent investigations demonstrating the safety of cluster schedules in atopic dermatitis, pediatric patients, and inhalant allergen mixtures and an accelerated protocol utilizing an infusion pump for allergen delivery. There has also been further elucidation on the immunological changes which occur during accelerated immunotherapy. Finally, new studies analyzing systemic reaction risk factors are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728613     DOI: 10.1007/s11882-013-0356-x

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  72 in total

1.  Accelerated immunotherapy schedules and premedication.

Authors:  Christopher W Calabria; Linda Cox
Journal:  Immunol Allergy Clin North Am       Date:  2011-05       Impact factor: 3.479

2.  Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment.

Authors:  G Lilja; B Sundin; V Graff-Lonnevig; G Hedlin; H Heilborn; K Norrlind; K O Pegelow; H Løwenstein
Journal:  J Allergy Clin Immunol       Date:  1989-01       Impact factor: 10.793

3.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma.

Authors:  J Bousquet; H J Maasch; A Hejjaoui; W Skassa-Brociek; R Wahl; H Dhivert; F B Michel
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793

4.  A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract.

Authors:  Penelope A Ewbank; Jacquelyn Murray; Karrie Sanders; Douglas Curran-Everett; Stephen Dreskin; Harold S Nelson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

5.  Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study.

Authors:  L Nielsen; C R Johnsen; H Mosbech; L K Poulsen; H J Malling
Journal:  J Allergy Clin Immunol       Date:  1996-06       Impact factor: 10.793

6.  Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.

Authors:  Oliver Pfaar; Ralph Mösges; Karl Hörmann; Ludger Klimek
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

7.  Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.

Authors:  G Hedlin; H Heilborn; G Lilja; K Norrlind; K O Pegelow; C Schou; H Løwenstein
Journal:  J Allergy Clin Immunol       Date:  1995-12       Impact factor: 10.793

8.  Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.

Authors:  R Schubert; O Eickmeier; H Garn; P C Baer; T Mueller; J Schulze; M A Rose; M Rosewich; H Renz; S Zielen
Journal:  Int Arch Allergy Immunol       Date:  2008-10-10       Impact factor: 2.749

9.  Premedication with montelukast reduces local reactions of allergen immunotherapy.

Authors:  Stefan Wöhrl; Simon Gamper; Wolfgang Hemmer; Georg Heinze; Georg Stingl; Tamar Kinaciyan
Journal:  Int Arch Allergy Immunol       Date:  2007-05-25       Impact factor: 2.749

10.  Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol.

Authors:  Vincenzo Patella; Giovanni Florio; Ada Giuliano; Carmine Oricchio; Giuseppe Spadaro; Gianni Marone; Arturo Genovese
Journal:  J Allergy (Cairo)       Date:  2012-05-24
View more
  8 in total

Review 1.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

Review 2.  Immunology of Bee Venom.

Authors:  Daniel Elieh Ali Komi; Farzaneh Shafaghat; Ricardo D Zwiener
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

3.  Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD).

Authors:  Oliver Pfaar; Tobias Ankermann; Matthias Augustin; Petra Bubel; Sebastian Böing; Randolf Brehler; Peter A Eng; Peter J Fischer; Michael Gerstlauer; Eckard Hamelmann; Thilo Jakob; Jörg Kleine-Tebbe; Matthias Volkmar Kopp; Susanne Lau; Norbert Mülleneisen; Christoph Müller; Katja Nemat; Wolfgang Pfützner; Joachim Saloga; Klaus Strömer; Peter Schmid-Grendelmeier; Antje Schuster; Gunter Johannes Sturm; Christian Taube; Zsolt Szépfalusi; Christian Vogelberg; Martin Wagenmann; Wolfgang Wehrmann; Thomas Werfel; Stefan Wöhrl; Margitta Worm; Bettina Wedi; Susanne Kaul; Vera Mahler; Anja Schwalfenberg
Journal:  Allergol Select       Date:  2022-09-06

4.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).

Authors:  Oliver Pfaar; Claus Bachert; Albrecht Bufe; Roland Buhl; Christof Ebner; Peter Eng; Frank Friedrichs; Thomas Fuchs; Eckard Hamelmann; Doris Hartwig-Bade; Thomas Hering; Isidor Huttegger; Kirsten Jung; Ludger Klimek; Matthias Volkmar Kopp; Hans Merk; Uta Rabe; Joachim Saloga; Peter Schmid-Grendelmeier; Antje Schuster; Nicolaus Schwerk; Helmut Sitter; Ulrich Umpfenbach; Bettina Wedi; Stefan Wöhrl; Margitta Worm; Jörg Kleine-Tebbe; Susanne Kaul; Anja Schwalfenberg
Journal:  Allergo J Int       Date:  2014

5.  A significant increase in expression of FOXP3 and IL-17 genes in patients with allergic rhinitis underwent accelerated rush immunotherapy.

Authors:  Amirabbas Salmani; Mojgan Mohammadi; Reza Farid Hosseini; Jalil Tavakol Afshari; Ali Fouladvand; Sajad Dehnavi; Maryam Khoshkhooi; Farahzad Jabbari Azad
Journal:  Iran J Basic Med Sci       Date:  2019-09       Impact factor: 2.699

6.  Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma.

Authors:  Giovanni Traina; Alberto Martelli; Salvatore Barberi; Amelia Licari; Gian Luigi Marseglia; Maria Angela Tosca; Giorgio Ciprandi
Journal:  Acta Biomed       Date:  2021-02-04

7.  An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial.

Authors:  A M Chaker; B Al-Kadah; U Luther; U Neumann; M Wagenmann
Journal:  Clin Transl Allergy       Date:  2016-02-02       Impact factor: 5.871

8.  Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study.

Authors:  Cristiano Caruso; Barbara Bramé; Diego Bagnasco; Alessia Cocconcelli; Valeria Ortolani; Valerio Pravettoni; Sergio Scarpa; Giuliana Zisa; Giovanni Passalacqua; Stefania Colantuono
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.